云天励飞更新招股书 专注于AI推理芯片的研发设计及商业化

Core Viewpoint - Shenzhen Yuntian Lifei Technology Co., Ltd. (Yuntian Lifei) is preparing for an IPO on the Hong Kong Stock Exchange, with a focus on AI inference chips and related products and services, positioning itself as a leading player in the Chinese AI market [1][4]. Company Overview - Yuntian Lifei is recognized as a leading AI company in China, specializing in the research, design, and commercialization of AI inference chips. The company integrates a deep understanding of AI algorithms and practical applications into its high-performance, cost-effective products [4]. - The company ranks among the top three providers of AI inference chip-related products and services in China, based on revenue projections for 2024 [4]. Product and Technology - The company's IFIC foundation enables algorithm chip integration, allowing for optimized chip designs that efficiently support multiple application scenarios. Key products include the NPU product Nova, AI inference chips (DeepEye, DeepEdge, and in-development products DeepVerse and DeepXBot), and the Hy3CAN hardware enabling tool and IFIE software platform [5]. - Yuntian Lifei's Nova product offers scalable AI inference capabilities applicable across edge and cloud environments, while the Hy3CAN tool provides a unified programming interface for chip capabilities [5]. Market Growth - The AI inference chip market in China is experiencing rapid growth, with market size projected to increase from 11.3 billion RMB in 2020 to 162.6 billion RMB by 2024, reflecting a compound annual growth rate (CAGR) of 94.9%. The market is expected to continue growing at a CAGR of 53.4% from 2024 to 2029, reaching 1.383 trillion RMB by 2029 [6]. Financial Performance - For the fiscal years 2022, 2023, and projected figures for 2024, Yuntian Lifei reported revenues of approximately 546.2 million RMB, 506.0 million RMB, and 917.4 million RMB, respectively. The company incurred losses of about 447.7 million RMB, 384.1 million RMB, and 572.2 million RMB during the same periods [7][8].